Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
11 10 2022
Historique:
entrez: 11 10 2022
pubmed: 12 10 2022
medline: 14 10 2022
Statut: ppublish

Résumé

Anxiety disorder, a common mental health condition in the US, comprises a group of related conditions characterized by excessive fear or worry that present as emotional and physical symptoms. The 2018-2019 National Survey of Children's Health found that 7.8% of children and adolescents aged 3 to 17 years had a current anxiety disorder. Anxiety disorders in childhood and adolescence are associated with an increased likelihood of a future anxiety disorder or depression. The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for anxiety disorders in children and adolescents. This is a new recommendation. Children and adolescents 18 years or younger who do not have a diagnosed anxiety disorder or are not showing recognized signs or symptoms of anxiety. The USPSTF concludes with moderate certainty that screening for anxiety in children and adolescents aged 8 to 18 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on screening for anxiety in children 7 years or younger. The USPSTF recommends screening for anxiety in children and adolescents aged 8 to 18 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for anxiety in children 7 years or younger. (I statement).

Identifiants

pubmed: 36219403
pii: 2797219
doi: 10.1001/jama.2022.16936
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1438-1444

Commentaires et corrections

Type : CommentIn
Type : SummaryForPatientsIn

Auteurs

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

University of North Carolina at Chapel Hill.

Michael Cabana (M)

Albert Einstein College of Medicine, New York, New York.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Karina W Davidson (KW)

Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

Carlos Roberto Jaén (CR)

The University of Texas Health Science Center, San Antonio.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Chan Medical School, Worcester.

John M Ruiz (JM)

University of Arizona, Tucson.

Michael Silverstein (M)

Brown University, Providence, Rhode Island.

James Stevermer (J)

University of Missouri, Columbia.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH